The IDIBELL research group on immunoinflammatory processes demonstrates that the C4BP (β-) protein could be a promising therapeutic option for inflammatory bowel disease.
Recent findings indicate a promising new therapeutic approach in the fight against cancer, involving a novel combination of treatments
The work has analyzed the interaction of the IKKα protein with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing the toxicity of the treatment.
New recommendations for the classification of variants in the POLE and POLD1 genes to improve diagnostic accuracy in hereditary cancer
The group has applied these classification recommendations to 128 variants reported in the literature and/or public databases, classifying 17 as pathogenic variants, and another 17 as benign.
Genetic studies that initially gave uncertain results can provide a reliable diagnosis if reviewed after two years
This Saturday took place the open day of the fifth edition of Sinergia, the celebration of health research and innovation in L’Hospitalet. More than 300 people came to the Bellvitge Campus to take part in the everyday work of that IDIBELL, the Catalan Institute of Oncology, the Bellvitge University Hospital, the University of Barcelona and the Hospital Sant Joan de Déu do to improve people’s health.
The Mediterranean diet and olive oil may benefit the prevention of some types of cancers related to obesity
A new study carried out by the Nutrition and Cancer research group of IDIBELL and the Catalan Institute of Oncology, with the collaboration of the scientific and technological center AZTI, offers a relevant review and update of data that demonstrates how eating habits and the microbiota intestine could play a key role in cancer prevention.
A new treatment to prevent infections acquired in the Intensive Care Unit (ICU) discovered by researchers from IDIBELL and the Bellvitge University Hospital enters the Clinical Phase
The new treatment is a drug that eliminates the antibodies that bind to gram-negative bacteria and makes them resistant to destruction by the immune system.
On the morning of Saturday, October 21, the 5th edition of Sinergia will bring the science of the Bellvitge Campus closer to citizens.
Researchers at CNIO and IDIBELL shed light on the role in lactation of a protein also crucial in breast cancer
When the RANK protein was suppressed in luminal cells of the breast tissue in female mice, they did not produce milk in their first pregnancy.
ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.